Skip to main content
    U

    Ultralife Corporation (ULBI)

    Official site

    INDUSTRIALS • ELECTRICAL EQUIPMENT & PARTS • NASDAQ

    $15.68
    -0.05 (-0.32%)

    Market Cap: $262.13M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    Ultralife Corporation (ULBI) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Ultralife (ULBI) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, Ultralife reported EPS of $0.14. It beat the EPS estimate in 0 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    26%(6/23)
    Avg Surprise
    -26.04%

    Next Report

    ULBI has an expected report date of Mar 8, 2027.

    ULBI Earnings Call

    The latest ULBI earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 23 quarters below that had an estimate, ULBI beat 6, missed 15 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $48.27M, up 11.3% from $43.37M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.14N/AN/AN/AN/A+100.0%N/AN/ANov 5, 2026$48.27M
    Jun 30, 2026$0.19$0.21N/A-9.52%Miss+171.4%N/AN/AJul 27, 2026$47.94M
    Mar 31, 2026-$0.03$0.15N/A-120.00%Miss-123.1%N/AN/AMay 8, 2026$47.45M
    Dec 31, 2025-$0.45$0.24N/A-285.71%Miss-4557.0%N/AN/AMar 10, 2026$48.48M
    Sep 30, 2025$0.07$0.21N/A-66.67%Miss+600.0%11 up, 0 downNov 18, 2025$43.37M
    Jun 30, 2025$0.07$0.14$0.14 - $0.14-50.00%Miss-61.1%10 up, 0 downAug 7, 2025$48.56M
    Mar 31, 2025$0.13$0.15$0.15 - $0.15-13.33%Miss-38.1%10 up, 1 downApr 1, 2025$50.75M
    Dec 31, 2024$0.01$0.15N/A-93.33%MissN/A10 up, 0 downDec 31, 2024$43.85M
    Sep 30, 2024$0.01$0.21N/A-95.24%Miss-90.0%N/A0 up, 0 downNov 8, 2024$35.69M
    Jun 30, 2024$0.18$0.14$0.14 - $0.14+28.57%Beat-14.3%10 up, 0 downJul 25, 2024$42.98M
    Mar 31, 2024$0.21$0.10$0.10 - $0.10+110.00%BeatN/A10 up, 0 downApr 25, 2024$41.93M
    Dec 31, 2023-$0.01$0.09N/A-111.11%MissN/AN/A0 up, 0 downFeb 15, 2024$44.55M
    Sep 30, 2023$0.10$0.10$0.10 - $0.100.00%In lineN/A10 up, 0 downOct 26, 2023$39.49M
    Jun 30, 2023$0.21$0.04$0.04 - $0.04+425.00%Beat+600.0%11 up, 0 downJul 27, 2023$42.69M
    Mar 31, 2023-$0.02-$0.09N/A+77.78%Beat-300.0%10 up, 0 downApr 27, 2023$31.92M
    Dec 31, 2022-$0.01$0.09N/A-111.11%MissN/AN/A0 up, 0 downMar 2, 2023$36.11M
    Sep 30, 2022-$0.01$0.06N/A-116.67%MissN/A10 up, 0 downOct 27, 2022$33.23M
    Jun 30, 2022$0.03$0.02N/A+50.00%Beat-50.0%10 up, 0 downJul 28, 2022$32.13M
    Mar 31, 2022$0.01-$0.05-$0.05 - -$0.05+120.00%Beat-80.0%10 up, 0 downApr 28, 2022$30.37M
    Dec 31, 2021-$0.09-$0.04-$0.04 - -$0.04-125.00%Miss-169.2%10 up, 0 downFeb 3, 2022$23.76M
    Sep 30, 2021-$0.05$0.08$0.08 - $0.08-162.50%Miss-266.7%1N/AOct 28, 2021$21.76M
    Jun 30, 2021$0.06$0.09N/A-33.33%Miss-40.0%N/AN/AJul 29, 2021$26.77M
    Mar 31, 2021$0.05$0.06N/A-16.67%Miss-28.6%N/AN/AApr 29, 2021$25.97M
    Dec 31, 2020$0.13$0.13N/A0.00%In line0.0%N/AN/AFeb 4, 2021$28.98M
    Sep 30, 2020$0.03N/AN/AN/AN/A-57.1%N/AN/AOct 29, 2020$24.36M
    Jun 30, 2020$0.10N/AN/AN/AN/A-44.4%N/AN/AJul 30, 2020$28.56M
    Mar 31, 2020$0.07N/AN/AN/AN/A+133.3%N/AN/AApr 30, 2020$25.81M
    Dec 31, 2019$0.13N/AN/AN/AN/A-89.3%N/AN/AFeb 6, 2020$31.02M
    Sep 30, 2019$0.07N/AN/AN/AN/A-22.2%N/AN/AOct 31, 2019$27.49M
    Jun 30, 2019$0.18N/AN/AN/AN/A+80.0%N/AN/AAug 1, 2019$29.40M
    Mar 31, 2019$0.03N/AN/AN/AN/A-76.9%N/AN/AMay 2, 2019$18.88M
    Dec 31, 2018$1.21N/AN/AN/AN/A+908.3%N/AN/AFeb 7, 2019$20.93M
    Sep 30, 2018$0.09N/AN/AN/AN/A+28.6%N/AN/ANov 1, 2018$20.33M
    Jun 30, 2018$0.10N/AN/AN/AN/A+42.9%N/AN/AAug 2, 2018$22.86M
    Mar 31, 2018$0.13N/AN/AN/AN/A+18.2%N/AN/AMay 3, 2018$23.07M
    Dec 31, 2017$0.12N/AN/AN/AN/A+5.6%N/AN/AFeb 8, 2018$22.51M
    Sep 30, 2017$0.07N/AN/AN/AN/A-38.8%N/AN/ANov 2, 2017$21.05M
    Jun 30, 2017$0.07N/AN/AN/AN/A+4.5%N/AN/AAug 3, 2017$19.94M
    Mar 31, 2017$0.11N/AN/AN/AN/A+276.7%N/AN/AMay 4, 2017$22.04M
    Dec 31, 2016$0.11N/AN/AN/AN/A+482.6%N/AN/AFeb 9, 2017$21.63M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.18, after $0.41 the year before. It was $0.32 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.18-142.9%
    Dec 31, 2024$0.41+46.4%
    Dec 31, 2023$0.28+1300.0%
    Dec 31, 2022$0.02N/A
    Dec 31, 2021-$0.03-109.1%
    Dec 31, 2020$0.33-19.5%
    Dec 31, 2019$0.41-73.2%
    Dec 31, 2018$1.53+313.5%
    Dec 31, 2017$0.37+14.1%
    Dec 31, 2016$0.32N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 3,100 words across 5 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20263,0915
    2026Q1Mar 31, 20262,7064
    2025Q4Dec 31, 20253,4035
    2025Q3Sep 30, 20252,8794
    2025Q2Jun 30, 20254,9666
    2025Q1Mar 31, 20254,1736
    2024Q3Sep 30, 20244,5197
    2024Q2Jun 30, 20243,6725

    2026Q2 Earnings Call

    Opening remarks

    Jody Burfening Head of Investor Relations Thank you, Lateef, and good morning, everyone. Thank you for joining us for Ultralife Corporation's Earnings Conference Call for the second quarter of fiscal 2026. With us on today's call are Mike Manna, Ultralife's President and CEO, and Phil Fain, Ultralife's Chief Financial Officer. The earnings press release was issued earlier this morning, and if anyone has not yet received a copy, I invite you to visit the company's website, www.ultralifecorp.com, where you'll find the release under Investor News in the Investor Relations section. Before turning the call over to management, I would like to remind everyone that some statements made during this conference call contain forward-looking statements based on current expectations. Actual results could differ materially from those projected as a result of various risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include uncertain global economic conditions, reductions in revenues from key customers, delays or reductions in U.S. and foreign military spending, acceptance of new products on a global basis, and disruptions or delays in supply of raw materials and components due to business conditions, global conflicts, weather, or other factors not under the company's control. The company cautions investors not to place undue reliance on forward-looking statements which reflect the company's analysis only as of today's date. The company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife's financial results is included in the company's filings with the Securities and Exchange Commission, including the latest quarterly report on Form 10-Q. In addition, on today's call, management will refer to certain non-GAAP financial measures that management considers to be useful and differ from GAAP. These non-GAAP measures should be considered supplemental to corresponding GAAP figures. With that, I would now like to turn the call over to Mike. Good morning, Mike.

    Michael Manna President & CEO Good morning. Welcome to Ultralife's Q2 2026 Earnings Call. Earlier today, we announced Q2 revenue of $47.9 million with operating profit of $3.4 million, which resulted in an EPS of $0.15 per share. We made positive progress on several fronts during the second quarter. We continue to build a strong and growing backlog, supported by an expanding product portfolio as recent product developments transition from development into commercialization. In addition, our new plant leaders in Newark and Raynham are continuing to gain experience and drive operational improvements. Their teams are executing key gross margin initiatives, which have begun to deliver measurable benefits and are expected to contribute further improvements as these efforts gain traction.

    Frequently Asked Questions About ULBI

    When is Ultralife's next earnings date?

    Ultralife's next earnings report is expected for Mar 8, 2027.

    How often does ULBI beat earnings estimates?

    Ultralife beat the EPS estimate in 0 of the 8 most recent quarters that had an estimate, with an average surprise of -91.73%.